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ABSTRACT 
 
Although recent research has demonstrated that 
pharmaceuticals are widely distributed in the aquatic 
environment, it is difficult to assess the threat that they 
pose to drinking water supplies or their rate of 
attenuation in natural systems without an adequate 
understanding of the sources of contamination.  To 
identify pharmaceutical compounds of significance to 
water supplies in the United States, we have reviewed 
available data on the use of prescription drugs.  Results 
of our analysis indicate that approximately 40 
compounds could be present in municipal wastewater 
effluent at concentrations above 1,000 ng/L and at least 
120 compounds could be present at concentrations 
above 1 ng/L.  Important classes of prescription drugs 
include analgesics, beta-blockers, and antibiotics. 
 
Analysis of a group of the most commonly used 
pharmaceuticals in the United States indicates that they 
are ubiquitous in wastewater effluents.  We have 
detected concentrations ranging from approximately 10-
3,000 ng/L for high use pharmaceuticals such as beta-
blockers (e.g., metoprolol, propranolol) and acidic drugs 
(e.g., gemfibrozil, ibuprofen).  The concentration of 
pharmaceuticals in effluent from conventional 
wastewater treatment plants is similar.  Advanced 
wastewater treatment plants equipped with reverse 
osmosis systems reduce concentrations of 
pharmaceuticals below detection limits.  In addition to 
removal during biological wastewater treatment, 
pharmaceuticals also are attenuated in engineered 
natural systems (i.e., treatment wetlands, ground water 
infiltration basins).  Preliminary evidence suggests 
limited removal of pharmaceuticals in engineered 
treatment wetlands and nearly complete removal of 
pharmaceuticals during ground water infiltration. 
 
INTRODUCTION 
 
During the 1990s, researchers in Germany and 
Switzerland reported the occurrence of numerous 
pharmaceuticals in municipal wastewater and in surface 
waters that receive wastewater effluent (Stan et al., 
1994; Hirsch et al., 1996; Stan & Heberer, 1996; Stumpf 
et al., 1996; Buser et al., 1998a; Buser et al., 1998b; 
Hartmann et al., 1998; Ternes, 1998; Buser et al., 1999; 
Hartig et al., 1999; Hirsch et al., 1999; Ternes & Hirsch, 
2000).  Preliminary results from studies conducted in 
North America have confirmed the presence of many of 
the same compounds (Metcalfe & Koenig, 2000; Sedlak 
et al., 2000; USGS 2001).  Despite these findings, our 
ability to predict the concentrations of pharmaceuticals 
in receiving waters and in potable water supplies is 
limited by a lack of understanding of the attenuation 
mechanisms of pharmaceuticals.  To predict the 
concentrations of pharmaceuticals in the aquatic 
environment and to design strategies to minimize 
exposure to pharmaceuticals, scientists and engineers 
must understand the processes that result in attenuation 
of pharmaceuticals both in wastewater treatment plants 
and in engineered receiving waters. 
 
Organic contaminants present in municipal wastewater, 
such as pharmaceuticals, may be removed or 
transformed by a variety of mechanisms.  In 
conventional wastewater treatment plants, 
pharmaceuticals can be removed by sorption to particles 
or by biotransformation.  In advanced wastewater 
treatment plants, such as those employed prior to 
indirect potable reuse, pharmaceuticals may be removed 
by physical separation processes (e.g., reverse osmosis).  
Finally, when wastewater effluent is discharged to 
engineered receiving waters, attenuation of 
pharmaceuticals also could occur through a combination 
of physical, biological, and photochemical processes. 
 
To develop a better understanding of the factors 
controlling concentrations of pharmaceuticals in the 
aquatic environment in the United States, we have 
studied the sources of pharmaceuticals in municipal 
wastewater and the effect of different treatment 
processes on concentrations of some of the most 
common pharmaceuticals present in municipal 
wastewater.  Results of our research suggest that it may 
be possible to design cost-effective approaches for 
minimizing concentrations of pharmaceuticals in the 
aquatic environment.  However, further research will be 
required to optimize these treatment systems. 
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ESTIMATION OF PHARMACEUTICAL CON-
CENTRATIONS IN MUNICIPAL WASTEWATER 
 
As mentioned previously, most available data on 
concentrations of pharmaceuticals have been collected 
in Europe.  To assess the occurrence of pharmaceuticals 
in the United States, it is necessary to identify those 
compounds that are most likely to be present.  To 
accomplish this goal, we have reviewed data on 
pharmaceutical use in the United States and studies on 
the occurrence of pharmaceuticals in Europe.  The 
purpose of our review is to identify compounds likely to 
be present at relatively high concentrations that can 
serve as indicators for the larger suite of 
pharmaceuticals. 
 
The first step in identifying pharmaceuticals meriting 
further study requires us to predict the concentrations of 
compounds present in water discharged by municipal 
and agricultural sources.  To achieve this goal, we have 
estimated concentrations in untreated wastewater for the 
most popular U.S. pharmaceuticals.  Estimates were not 
made for less popular drugs, nonprescription drugs, and 
drugs used mainly in hospitals (e.g., X-ray contrast 
media, cancer chemotherapy drugs) because sales data 
were unavailable. 
 
Our approach for estimating the concentrations of 
prescription drugs involved dividing the mass of drug 
excreted by patients by the volume of wastewater 
discharged to municipal wastewater treatment plants.  
Calculations were performed for the top 200 
prescription drugs listed in a 1998 survey conducted by 
IMS Health (1999).  The top 200 prescription drugs 
include 136 compounds because some of the drugs 
contain the same active ingredient.  Because numerous 
assumptions are needed to convert the number of 
prescriptions administered to the concentration of 
pharmaceuticals in municipal wastewater, considerable 
uncertainty is associated with these estimates.  Despite 
the uncertainties, the estimates are useful in identifying 
pharmaceuticals that are candidates for further study. 
 
Estimation of the concentrations of pharmaceuticals in 
municipal wastewater required the conversion of the 
number of prescriptions administered into the mass of 
compound discharged.  Because several formulations 
are available for each prescription drug, the mass of 
active ingredient in a dose varies between prescriptions.  
For example, the b-blocker timolol is prescribed at 40 
mg/prescription in an oral formulation and 6 
mg/prescription in an eye ointment.  To estimate the 
mass of active drug associated with each dose, we 
consulted medical reference books (Katzung 1998, PDR 
1999) and interviewed a practicing pharmacist who 
provided information on the most popular form of each 
prescription of interest.  After estimating the mass of 
active ingredient in each dose of the most popular form 
of the drug, we estimated the number of doses per 
prescription.  Estimates were made for the maximum 
and minimum masses per prescription assuming the 
most common drug formulations.  For drugs that were 
given on a one-time basis (e.g., antibiotics), we assumed 
that each prescription included a sufficient number of 
doses to treat the ailment (typically 10 days).  For drugs 
administered on a continuing basis (e.g., beta-blockers, 
birth control pills) we assumed that each prescription 
was renewed monthly.  The basis for this assumption 
was the current practices of many health maintenance 
organizations (HMOs) to refill prescriptions once per 
month. 
 
After estimating the mass of each drug prescribed, we 
estimated the concentration present in untreated 
wastewater (results for those compounds predicted to be 
present at concentrations above 1,000 ng/L are included 
in Table 1).  The values given in Table 1 represent the 
geometric mean of estimates based on the upper and 
lower bound estimates.  When excretion data were 
readily available, we estimated the fraction of the dose 
excreted in its original form.  However, excretion data 
were not readily available for many drugs, or when the 
data were available, it was unclear if glucuronide or 
sulfate conjugates were considered to be transformation 
products.  Since the conjugates appear to be converted 
back into their original unconjugated forms prior to, or 
during wastewater treatment, conjugated forms of drugs 
should be included with the parent compound.  As a 
result of missing or ambiguous data, information on 
metabolism was only available for 30 percent of the 
pharmaceuticals in the top 200 list.  Therefore, 
comparisons between estimated concentrations of 
PhACs are made without consideration of metabolism.  
No attempts were made to quantify active metabolites. 
 
Estimated concentrations of prescription drugs in 
untreated wastewater (only the top 49 drugs are 
included in Table 1) range from less than 1 ng/L to 
approximately 133,000 ng/L.  The estimated 
concentrations are distributed over a wide range with 
the majority of compounds estimated to be present at 
concentrations between 100 and 1,000 ng/L.  In general, 
the compounds expected to be present at the highest 
concentrations consisted of analgesics (e.g., 
acetominophen, ibuprofen) and antibiotics (e.g., 
amoxicillin, cephalexin).  Because some of the 
analgesics on the list also are available as over-the-
counter products, their concentrations in wastewater 
could be considerably higher. Compounds estimated to 
be present at the lowest concentrations tended to be 
potent drugs such as hormones (e.g., 
medroxyprogresterone, equilin).  Therefore, compounds  
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Table 1: Estimated concentrations of popular prescription drugs in untreated wastewater in the United States.   
 
 
Excluding Metabolism Including Metabolism
Name Classification  Predicted Wastewater Conc. (1) (ng/L) 
 Predicted Wastewater Conc. (1) 
(ng/L) 
Excretion 
(2)
acetominophen analgesic 61,000 53,000 C
ibuprofen analgesic, anti-inflammitory 37,000 B
amoxicillin antibiotic 27,000 16,000 D
metformin antidiabetic 24,000 21,000 D
cephalexin               antibiotic 14,000 12,000 D
nabumetone analgesic, anti-inflammitory 12,000 F
azithromycin antibiotics 9,200 J
oxaprozin analgesic, anti-inflammitory 6,600 B
sodium valproate anticonvulsant 6,000 2,400 H
gabapentin anticonvulsant 5,400 5,400 D
carisoprodol skeletal muscle relaxant 5,100 J
penicillin antibiotic 4,000 J
sulfamethoxazole antibiotic 3,800 3,200 G
gemfibrozil cholesterol lowering 3,400 D
metoprolol b-blocker 3,100 160 B
ciprofloxacin antibiotic 3,100 1,400 G
ranitidine H2-receptor antagonist 3,000 J
mupirocin antibiotic 2,800 A
clarithromycin antibiotic 2,800 680 F
phenytoin anticonvulsant 2,700 A
diltiazem calcium channel blocker 2,600 79 A
naproxen analgesic, anti-inflammitory 2,400 C
verapamil calcium channel blocker 2,400 85 J
ipratropium bronchiodiolater 2,400 E
trimethoprim antibiotic 2,200 1,500 J
tramadol analgesic 2,200 640 E
cimetidine H2-receptor antagonist 2,200 1,000 D
clavulanic acid antibiotic 2,100 680 E
propoxyphene opiod analgesic 2,100 J
bupropion antidepressant 2,100 F
hydrochlorothiazide diuretic 1,900 1,200 D
troglitazone antidiabetic 1,800 B
cefprozil antibiotic 1,700 1,000 J
pseudoephedrine decongestant 1,600 J
erythromycin antibiotic 1,500 75 I
atenolol b-blocker 1,500 1,500 D
sertraline antidepressant 1,400 180 F
triamterene diuretic 1,400 J
nefazodone antidepressant 1,300 13 F
tetracycline antibiotic 1,200 J
allopurinol antigout 1,000 F
(1)  This calculation was made assuming that the population of the U.S. is 250 million, that each person produces 320 L of wastewater per day, 
and that the excreted pharmaceuticals are evenly distributed among all wastewater in the U.S.
(2)  (A)  Extensive metabolism to inactive metabolites
(B) Extensive metabolism, possibly to conjugates
(C) Excreted mostly as conjugates
(D) Excreted mostly in original form (>50%)
(E) Excreted partially in original form (25-50%)
(F) Extensive metabolism to active metabolites
(G) Excreted as mixture of conjugates/original form
(H) Excreted partially as conjugates (25-50%)
(I) Little excreted in urine
(J) Data on metabolism not obtained
References for doses and metabolism:
Katzung, B.G. 1998. Basic and Clinical Pharmacology.   Stamford, CT: Appleton and Lange.
Physicians' Desk Reference.  1999.  Montvale, NJ:  Medical Economics Company, Inc.
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estimated to be present at low concentrations should not 
be eliminated from further consideration without 
considering issues related to potency.  However, such 
compounds will be extremely difficult to detect using 
conventional analytical techniques. 
 
After considering the predicted concentrations of 
pharmaceuticals, the availability of suitable analytical 
techniques and data on the occurrence of 
pharmaceuticals in Europe, we identified a subset of 
compounds to serve as indicators for pharmaceuticals in 
wastewater effluent.  In several cases, compounds were 
included even though they were not expected to be 
present at high concentrations because they could be 
analyzed readily with the selected analytical methods.  
Excluding antibiotics, which are be discussed elsewhere 
(Huang et al., 2001), our list included six acidic drugs 
(i.e., diclofenac, gemfibrozil, ibuprofen, indometacine, 
ketoprofen and naproxen) and three beta-blockers (i.e., 
metaprolol, nadolol and propranolol). 
 
 
MATERIALS AND METHODS 
 
Samples collected from wastewater treatment plants and 
engineered receiving waters were subjected to solid-
phase extraction and were analyzed for pharmaceuticals 
using gas chromatography/tandem mass spectrometry 
(i.e., GC/MS/MS) and immunoassays.  Details of the 
analytical methods have been, or will be, reported 
elsewhere.  Therefore, we have only provided a brief 
description of our approach. 
 
Between 1 to 4 liters of samples were filtered through 
0.45-mm glass fiber filters followed by solid phase 
extraction.  For the acidic drugs, the sample pH was 
adjusted to pH less than 2 with sulfuric acid followed by 
extraction using endcapped C-18 resin.  For neutral 
drugs and beta-blockers, the solid phase consisted of C-
18 resin.  For hormones, a C-18 Empore disc was used 
for solid phase extraction.   
 
Samples to be analyzed for acidic drugs or beta-blockers 
were eluted from the resins using methanol followed by 
derivitization.  For the acidic drugs, we used a 
diazomethane/diethylether mixture for derivitization.  
The beta-blockers were derivitized using MSTFA 
followed by MBTFA.  Samples were analyzed by 
GC/MS/MS using a 30-meter DB-5 column.  Internal 
standards were added to each sample to monitor 
extraction and derivitization efficiency as well as GC 
performance.  Typical detection limits for 
pharmaceuticals in wastewater effluent were around 10 
ng/L. 
Analysis of hormones was performed by modification 
of a previously published immunoassay approach 
(Huang & Sedlak, 2000).  Samples were eluted from the 
Empore disc using a methanol water mixture followed 
by dual column cleanup using gel permeation 
chromatography followed by reverse-phase 
chromatography.  The detection limit for 17b-estradiol 
and 17a-ethinyl estradiol was approximately 0.02 ng/L.  
Confirmatory analysis was conducted using 
GC/MS/MS. 
 
ATTENUATION OF PHARMACEUTICALS 
 
To assess factors controlling the concentrations of 
pharmaceuticals in receiving waters, we measured 
concentrations of pharmaceuticals present after different 
treatment processes.  Additional analyses are underway 
and we plan on publishing complete results of these 
studies during the coming year.  Therefore, the results 
presented here should be considered preliminary.  
However, they do illustrate the relative significance of 
different mechanisms that can be pursued in more detail 
as part of future investigations.  In the following 
sections, we describe the attenuation mechanisms and 
available data for each of the different treatment 
processes. 
 
Conventional Wastewater Treatment Plants 
 
Two attenuation mechanisms are potentially important 
for the removal of pharmaceuticals in conventional 
wastewater treatment plants: (1) sorption to particles 
followed by settling and removal; and, (2) 
biotransformation.  The relative importance of these 
mechanisms will be controlled by the configuration of 
the treatment plant, the physical and chemical properties 
of the compounds and the concentrations of the 
compounds. 
 
During primary and secondary wastewater treatment, 
particles are efficiently removed.  Therefore, any 
pharmaceutical with a high affinity for particles also 
will be removed in the sludge.  (If these compounds are 
not transformed prior to sludge disposal, they could lead 
to an additional exposure pathway that is not considered 
further in this paper.)  Sorption of pharmaceuticals to 
particles present in wastewater treatment plants can 
occur either via hydrophobic or electrostatic interactions 
(e.g., ion exchange, surface complexation). 
 
For hydrophobic interactions, the octanol/water partition 
coefficient is a good predictor of the affinity of the 
compound for the solid phase.  Under the conditions 
encountered in conventional wastewater treatment 
plants, only those compounds with octanol/water 
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partition coefficients greater than approximately 100 
will be removed to an appreciable degree (Sedlak et al., 
2000).  With the exception of the steroid hormones, 
which have octanol/water partition coefficients of 
approximately 10,000, few pharmaceuticals meet this 
criterion.  Therefore, we do not expect this mechanism 
to result in substantial removal of pharmaceuticals. 
 
Sorption of pharmaceuticals via other interactions 
usually requires the presence of acidic, phenolic, or 
amino functional groups.  Although many of the 
pharmaceuticals contain such functional groups, 
removal via these mechanisms is not expected to be 
significant under the conditions encountered in 
municipal wastewater.  However, some antibiotics 
appear to undergo sorption via ion exchange reactions. 
 
Removal of pharmaceuticals also can occur via 
biotransformation.  Predicting the relative importance of 
biotransformation from chemical structure is 
notoriously difficult.  Furthermore, compounds that are 
metabolized by microorganisms at relatively high 
concentrations may not be transformed to an 
appreciable degree when present at the extremely low 
concentrations encountered in wastewater.  Available 
data from full-scale wastewater treatment plants suggest 
that certain compounds, such as ibuprofen, are readily 
degraded while other compounds, such as and 
carbamazepine, are removed to a much smaller extent 
(Ternes, 1998; Buser et al., 1999). 
 
Preliminary results from our survey of wastewater 
treatment plants are consistent with these findings 
(Figure 1).  The horizontal lines included in the figure, 
which represent our estimate of pharmaceutical 
concentrations in untreated wastewater (i.e., Table 1), 
allow us to compare expected influent concentration 
with observed effluent concentrations.  These results 
indicate that more than 99 percent of the ibuprofen is 
removed during secondary wastewater treatment while 
less than half of the gemfibrozil and propranolol are 
removed during secondary treatment. 
 
 
Figure 1: Concentrations of selected pharmaceuticals detected in final effluent collected from secondary (filled 
bars) and tertiary (hollow bars) municipal wastewater treatment plants.  Horizontal lines indicate estimated 
concentrations in untreated wastewater. 
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The six pharmaceuticals depicted in Figure 1 were 
detected in wastewater effluent samples at 
concentrations ranging from approximately 10 to 3,000 
ng/L.  Concentrations detected in secondary effluent 
samples (filled bars) were similar for all four sites.  For 
the two sites that also employed nitification (hollow 
bars) concentrations at the first site, which is a trickling 
filter followed by a nitrification tower, were comparable 
to those detected in the secondary effluent samples; 
while concentrations detected at the second site, which 
employed activated sludge followed by nitrification, 
exhibited significantly lower concentrations. 
 
Advanced Wastewater Treatment Plants 
 
Indirect potable reuse projects equipped with state-of-
the-art advanced wastewater treatment plants have been 
operated in several locations in the United States for 
over twenty-five years (NAS, 1998; Sedlak et al., 2000).  
To remove pathogens and chemical contaminants, many 
of these facilities employ membrane treatment.  
Currently, the most common configuration for these 
systems involves the use of lime coagulation or 
microfiltration to remove colloids followed by reverse 
osmosis.  Because the polar pharmaceuticals should not 
be associated with particles, we expect little removal to 
occur during lime clarification or microfiltration.  In 
contrast, reverse osmosis should remove most of the 
pharmaceuticals that have molecular weights above 
approximately 200 gm/mole. 
 
Measurements of the concentrations of pharmaceuticals 
at the West Central Basin Ground water Replenishment 
Project, an advanced wastewater treatment plant that 
uses microfiltration and thin-film composite reverse 
osmosis membranes, are consistent with these 
expectations (Figure 2).  Concentrations of 
pharmaceuticals measured before and after 
microfiltration are nearly identical.  Concentrations of 
pharmaceuticals decrease to levels below detection 
limits after reverse osmosis treatment.  These results 
suggest that full-scale reverse osmosis systems 
effectively remove these polar pharmaceuticals. 
 
 
 
 
Figure 2: Concentrations of pharmaceutical measured after different unit processes at the West Central Basin 
Ground water Replenishment Project.  After reverse osmosis treatment concentrations, of all pharmaceuticals are 
below 10 ng/L. 
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Engineered Receiving Waters 
 
After conventional or advanced wastewater treatment, 
engineered receiving waters may be used to further 
attenuate contaminants, especially when water is being 
reused or discharged into a sensitive aquatic habitat.  In 
the United States, the most common types of engineered 
receiving waters are surface engineered treatment 
wetlands and ground water infiltration basins.  Although 
most of the attenuation mechanisms found in 
wastewater treatment plants also will occur in these 
systems, changes in environmental conditions (e.g., less 
organic matter available for metabolism) could alter the 
rates of transformation reactions.  Furthermore, new 
attenuation mechanisms may also be important in these 
systems (e.g., phototransformation in wetlands).  To 
assess these processes, we have analyzed concentrations 
of pharmaceuticals in samples from engineered 
receiving waters. 
 
In ground water infiltration basins, the microbial 
community metabolizes many organic compounds 
(Drewes & Fox, 1999).  The biological processes 
occurring during infiltration, which are sometimes 
referred to as soil aquifer treatment, could provide a 
means of removing pharmaceuticals that pass through 
conventional wastewater treatment systems.  To assess 
the efficacy of soil aquifer treatment systems, we 
collected samples from the Sweetwater Ground water 
Recharge Facility, located in Tuscon, Arizona.  The 
facility consists of an infiltration basin that receives 
secondary wastewater effluent that replenishes a deep 
aquifer.  Samples collected from the recharge pond, a 
shallow well (screened at 5 meters below the basin) and 
a deep well (screened at 40 meters below the basin) 
indicate that little removal occurs during the initial 
stages of infiltration and that all of the compounds are 
removed between the shallow and deep well.  Because 
previous studies have indicated that almost all of the 
water sampled by the deep well originated in the 
infiltration basin, these data suggest that the 
pharmaceuticals are attenuated during passage through 
the aquifer.  However, it should be noted that previous 
sampling of the deep well indicated the presence of 
several pharmaceuticals at concentrations as high as 50 
ng/L (data not shown). 
 
 
 
Figure 3: Concentrations of pharmaceuticals measured after ground water infiltration at the Sweetwater Ground 
water Recharge Site in Tuscon, Arizona.  Concentrations of all compounds measured in the deep ground water well 
were below detection limits. 
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Pharmaceuticals also could be removed during passage 
through engineered treatment wetlands.  Attenuation 
mechanisms of potential importance in engineered 
treatment wetlands include biotransformation, 
photolysis, and hydrolysis.  To assess losses of 
contaminants during passage through treatment 
wetlands, we have measured concentrations of 
pharmaceuticals at locations throughout an engineered 
treatment wetland that receives nitrified wastewater 
effluent.  Samples were collected at the exit weirs from 
several wetland cells located along the flow path of the 
water.  Previous tracer studies at the wetland indicate a 
hydraulic residence time of approximately seven days.  
Little or no loss of pharmaceuticals was observed during 
passage through the treatment wetland (data not shown).  
In contrast, significant losses of the estrogenic hormone, 
17a-estradiol were observed: influent concentrations 
decreased from approximately 2 ng/L in the first pond 
to less than 0.5 ng/L in the final pond.  Because ethinyl 
estradiol is resistant to biotransformation in activated 
sludge treatment systems, we hypothesize that the 
observed transformation is attributable to some other 
process, such as indirect photolysis. 
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